Pharmaceutical - Markets & Marketing, Amgen


Current filters:

Markets & MarketingAmgen

Popular Filters

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023


The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

US nephrologists view hyperphosphatemia treatment

US nephrologists view hyperphosphatemia treatment


Surveyed nephrologists report awareness of the US Food and Drug Administration's approval of Vifor Fresenius…

AmgenFreseniusGlaxoSmithKlineLa Jolla PharmaceuticalMarkets & MarketingNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeSensiparUSAvelcalcetideVelphoroVenoferVifor Pharma

Pharmaceutical companies to benefit from new blood cancer drugs


Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Pipeline innovation bodes well for systemic lupus erythematosus market


While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report


Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022


After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market


From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA


The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Switch to anabolics driving osteoporosis market growth


A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021


Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA


US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Enbrel gets highest rating among RA biologicals by surveyed US patients


For surveyed rheumatoid arthritis (RA) patients on biologic therapy, the benefits outweigh the risks…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelMarkets & MarketingmethotrexateNorth AmericaPfizerPharmaceutical

Abbott/Eisai's Humira has emerged as leading psoriasis agent


For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan


Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Global osteoporosis market report sees strong showing in China


The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

Back to top